Summary
49 / 100 · Bulios Score
Valuation 100Growth 100Profitability 0Quality 3Debt 69Stability 26
What speaks for it
- Revenue grew by 41% a year over the last 3 years.
- The price moves less than the market (beta 0.69).
What to watch
- The company made a loss over the last 12 months.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
2019202020212022202320252026
Diluted EPS (USD)
2019202020212022202320252026
- Analyst estimate
Revenue grew by 41% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments $41.0M
Debt $44.3M
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.